Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:30 AM ET Form 4
Insider Selling Amalgamated Financial Corp. AMAL

Amalgamated Financial Insider United Workers Sells $4.72M of Stock

United Workers sold 92,809 shares of Amalgamated Financial Corp. at $50.86 a share, worth $4.72M in total on Nov 4, 2026. Shares held after the trade: 6,747,407 (-1.4%).

Value
$4.72M
Shares
92,809
Price
$50.86
Holding change
-1.4%
Trade date
Nov 4, 2026
8:28 AM ET 10-Q
Financial Results 1 800 Flowers Com Inc FLWS ▶ Call

1 800 Flowers Com Q1 2026 Results: Net Loss of $54.3M, Loss Widens

1-800-FLOWERS.COM, Inc. reported its fiscal first quarter results for the period ended September 2026, reflecting typical seasonal trends with a focus on operational efficiency. The company continues to navigate consumer spending shifts while preparing for the peak holiday season.

Key figure
Net loss $54.3M
8:28 AM ET Form 4
Insider Selling Amalgamated Financial Corp. AMAL

Amalgamated Financial Insider States Regional Joint Board Workers United Western Sells $4.72M of Stock

States Regional Joint Board Workers United Western sold 92,809 shares of Amalgamated Financial Corp. at $50.86 a share, worth $4.72M in total on Nov 4, 2026. Shares held after the trade: 6,747,407 (-1.4%).

Value
$4.72M
Shares
92,809
Price
$50.86
Holding change
-1.4%
Trade date
Nov 4, 2026
8:23 AM ET 8-K
Capital Raise 60 Degrees Pharmaceuticals, Inc. SXTP

60 Degrees Pharmaceuticals Capital Raise of $526K

60 Degrees Pharmaceuticals entered into inducement agreements with warrant holders to exercise existing warrants for 584,492 shares at a reduced price of $0.90 per share. In exchange for the cash exercise, the company will issue new unregistered warrants for up to 1,168,984 shares. The company expects to receive gross proceeds of approximately $526,042 to be used for working capital and general corporate purposes.

Value
$526K
8:21 AM ET 8-K
Financial Results Tredegar Corp TG

Tredegar Financial Results

Tredegar Corporation reported a net loss from continuing operations of $2.8 million for the third quarter of 2026, compared to net income of $7.1 million in the prior year period. Results were negatively impacted by lower shipments in the Aluminum Extrusions segment and resin-cost pressures in High Performance Films. CEO Dr. Arijit DasGupta highlighted the ongoing 'One Tredegar' initiative aimed at simplifying the organization and improving operating performance.

Term
Q3 2026

“We are well on the way on our journey to re-engineer Tredegar into a stronger operating company and create sustainable shareholder value.”

Dr. Arijit (Bapi) DasGupta, president and chief executive officer

“Looking at our third-quarter results – clearly – they were not where we want them to be. We faced broader market pressures, but we also have areas where we need to better execute.”

Dr. Arijit (Bapi) DasGupta, president and chief executive officer
8:19 AM ET Form 4
Insider Selling InterDigital, Inc. IDCC

InterDigital CTO Rajesh Pankaj Sells $461K of Stock

Rajesh Pankaj, CTO, sold 1,500 shares of InterDigital, Inc. at $307.38 a share, worth $461K in total on Nov 5, 2026. Shares held after the trade: 62,050 (-2.4%).

Value
$461K
Shares
1,500
Price
$307.38
Role
CTO
Holding change
-2.4%
Trade date
Nov 5, 2026
8:19 AM ET 10-Q
Financial Results Tredegar Corp TG

Tredegar Q3 2026 Results: Net Loss of $2.82M

Tredegar Corp reported net income of $8.86 million for the first nine months of 2026, a decrease from $18.91 million in the prior year period. While sales increased to $609.9 million, the company experienced a net loss of $2.82 million in the third quarter of 2026 due to higher cost of goods sold and asset impairment charges.

Key figure
Net loss $2.82M
8:16 AM ET 8-K
Other 8-K Filing Wheeler Real Estate Investment Trust, Inc. WHLR

Wheeler Real Estate Investment Trust Other 8-K Filing

Wheeler Real Estate Investment Trust settled the redemption of 1,903 shares of Series D Preferred Stock by issuing 74,374 shares of common stock at a volume-weighted average price of $1.07. This redemption triggered a downward adjustment of the conversion price for the company's 7.00% Subordinated Convertible Notes due 2031 to approximately $0.59 per share.

8:15 AM ET 8-K
Other 8-K Filing Chain Bridge I CBRRF

Chain Bridge I Other 8-K Filing

Chain Bridge I (a SPAC) held an extraordinary general meeting where shareholders approved extending the deadline to complete an initial business combination from November 15, 2026, to November 15, 2027. Additionally, the company amended a $1.25 million promissory note held by C/M Capital Master Fund LP to extend its maturity date to match the new November 2027 deadline.

Counterparty
C/M Capital Master Fund LP
Term
through Nov 2027
8:15 AM ET Form 4
Insider Buying ProMIS Neurosciences Inc. PMN

ProMIS Neurosciences Insider Eugene Williams Buys $90.9K of Stock

Eugene Williams bought 26,500 shares of ProMIS Neurosciences Inc. at $3.43 a share, worth $90.9K in total on Nov 4, 2026. Shares held after the trade: 40,213 (+193.2%).

Value
$90.9K
Shares
26,500
Price
$3.43
Holding change
+193.2%
Trade date
Nov 4, 2026
8:14 AM ET 8-K
Financial Results Koppers Holdings Inc. KOP

Koppers Holdings Financial Results

Koppers Holdings reported Q3 2026 sales of $499.1 million, a 2.8% increase year-over-year, though net income fell 38.2% to $14.7 million due to higher raw material and logistics costs. Despite margin pressure in its Railroad and Carbon Materials segments, the company achieved record year-to-date operating cash flow of $126.9 million and reduced total debt by $31.0 million.

Term
Q3 2026

“Our third-quarter results reflect continued challenges in the macroeconomic environment. While we are delivering on our commitments to grow volumes and structurally improve our cost position, higher raw material and logistics costs are more than offsetting those benefits in the near term, placing additional pressure on margins and earnings.”

Leroy Ball, Chief Executive Officer and Chair
8:11 AM ET 8-K
Financial Results Global Partners LP GLP

Global Partners Financial Results

Global Partners LP reported third quarter 2026 net income of $52.4 million, a significant increase from $29.0 million in the prior year period. The results were driven by strong performance in the Wholesale segment, which offset lower retail fuel volumes in the GDSO segment. The company also highlighted its improved capital structure following the redemption of Series B preferred units and a credit facility extension.

Term
Q3 2026

“Our third quarter results demonstrate the strength of our integrated liquid energy model, with strong growth in both EBITDA and distributable cash flow year over year. Solid execution across our terminal network and Wholesale business more than offset lower retail fuel volumes as higher pump prices weighed on demand, and our station operations held steady. That balance reflects the resilience of our integrated model.”

Eric Slifka, the Partnership’s President and Chief Executive Officer

“We continue to strengthen our capital structure. The July redemption of our Series B preferred units and the extension of our credit facility to 2031 give us greater flexibility. With strong distribution coverage and low leverage, we are well positioned to invest in the business, return cash to unitholders, and pursue compelling opportunities with discipline.”

Eric Slifka, the Partnership’s President and Chief Executive Officer
8:11 AM ET 10-Q
Financial Results Protara Therapeutics, Inc. TARA

Protara Therapeutics Q3 2026 Results: Net Loss of $21.7M, Loss Widens

Protara Therapeutics reported a net loss of $61.1 million for the nine months ended September 30, 2026, compared to a $40.1 million loss in the prior year, driven primarily by a significant increase in research and development expenses. As of September 30, 2026, the company maintained $127.1 million in cash, cash equivalents, and marketable debt securities to fund its clinical pipeline, including TARA-002 and IV Choline Chloride.

Key figure
Net loss $21.7M
8:10 AM ET 8-K/A
Financial Results Lifetime Brands, Inc LCUT

Lifetime Brands Financial Results

Lifetime Brands reported Q3 2026 financial results with net sales of $177.7 million, a 3.4% increase year-over-year, driven by 18.8% growth in international sales. The company also announced a new $20 million share repurchase authorization and reaffirmed its momentum in home décor and its Farberware relaunch. This filing is an amendment to clarify Adjusted EBITDA figures for the trailing twelve-month period.

“We delivered net sales growth of 3.4% and expanded gross margin by 140 basis points in the third quarter as momentum continues across key parts of the business. International sales grew 18.8% and the segment approached breakeven as Project Concord takes hold.”

Rob Kay, Lifetime's Chief Executive Officer
8:09 AM ET 10-Q
Financial Results Utz Brands, Inc. UTZ

Utz Brands Q3 2026 Results: Net Loss of $24.3M, Loss Widens

Utz Brands reported a net loss of $50.5 million for the thirty-nine weeks ended September 27, 2026, compared to a $4.4 million loss in the prior year period, driven by higher selling and administrative expenses. The company is currently navigating a proposed transaction with the Intersnack Group, which has resulted in significant transaction costs and management diversion.

Key figure
Net loss $24.3M
8:08 AM ET 10-Q
Financial Results Aligos Therapeutics, Inc. ALGS

Aligos Therapeutics Q3 2026 Results: Net Loss of $21.9M, Loss Narrows

For the nine months ended September 30, 2026, Aligos Therapeutics reported a net loss of $46.4 million, a significant increase from the $4.3 million loss in the prior year period. While total revenue grew to $33.5 million due to a $27.8 million licensing agreement, the prior year's results were heavily skewed by a $59.0 million non-cash gain from the change in fair value of common warrants.

Key figure
Net loss $21.9M
8:06 AM ET 8-K
Financial Results Protara Therapeutics, Inc. TARA

Protara Therapeutics Financial Results

Protara Therapeutics reported third quarter 2026 financial results and provided a clinical pipeline update, including the expected completion of enrollment for its TARA-002 registrational cohort in NMIBC by year-end. The company also announced an $8.75 million asset purchase agreement with Novex Innovations for manufacturing-related assets and reported a cash position of $143 million, sufficient to fund operations into 2028.

“Protara continues to deliver across our late-stage portfolio, advancing each of our programs toward its next key clinical and regulatory milestone. This steady progress positions us to close out the year with strong momentum and sets the stage for an impactful 2027.”

Jesse Shefferman, Chief Executive Officer at Protara Therapeutics

“TARA-002 has the potential to be a preferred treatment option for patients with non-muscle invasive bladder cancer (NMIBC), and we are on track to complete enrollment of the BCG-Unresponsive registrational cohort by year-end, a key step toward bringing this therapy to patients.”

Jesse Shefferman, Chief Executive Officer at Protara Therapeutics
8:03 AM ET 10-Q
Financial Results Clover Health Investments, Corp. CLOV

Clover Health Investments Q3 2026 Results: Turns Profitable, Net Income $6.43M

Clover Health Investments, Corp. is a remote-first healthcare technology company that operates as a large accelerated filer. As of October 30, 2026, the company had 439,707,261 shares of Class A and 95,713,497 shares of Class B common stock outstanding. The filing highlights the expansion of its Clover Assistant technology under the brand name Counterpart Assistant for external payors and providers.

Key figure
Net income $6.43M
8:02 AM ET 8-K
Financial Results Calumet, Inc. CLMT

Calumet Financial Results

Calumet reported Q3 2026 net income of $273.3 million and Adjusted EBITDA with Tax Attributes of $347.2 million, driven by strong performance in Specialty Products and record earnings from Montana Renewables. The company continued its deleveraging strategy, retiring approximately $265 million of debt since July 2026.

Term
Q3 2026

“The third quarter was exceptional for Calumet, with both of our businesses delivering outstanding results and our deleveraging and growth strategy accelerating by years.”

Todd Borgmann, CEO

“Our performance reflects a strong market and years of deliberate positioning through our integrated specialties platform supported by advantaged domestic crude, a world-class renewables business, and a commercial and operational organization executing at an increasingly high level.”

Todd Borgmann, CEO
8:02 AM ET 10-Q
Financial Results Strive, Inc. ASST

Strive Q3 2026 Results: Net Income $509M

Strive, Inc. reported a significant increase in total assets to $2.68 billion as of September 30, 2026, primarily driven by a surge in the fair value of digital assets to $2.34 billion. Despite a net loss of $14.5 million for the nine months ended September 30, 2026, the company achieved a net income of $509 million in the third quarter, largely due to $533.7 million in unrealized gains on digital assets.

Key figure
Net income $509M
8:01 AM ET 8-K
Investor Presentation Georgia Banking Co Inc GBC

Georgia Banking Co Investor Presentation

Georgia Banking Company, Inc. filed a formal investor presentation containing strategic discussion materials and financial information for the third quarter of 2026. Management intends to use these materials in meetings with investors and analysts beginning November 9, 2026, to discuss the company's performance and strategic initiatives in the Atlanta market.

8:01 AM ET 8-K
Financial Results Dauch Corp DCH

Dauch Financial Results

Dauch Corporation reported Q3 2026 financial results, with sales increasing to $2.91 billion primarily driven by the acquisition of Dowlais. The company reported a net loss of $45.3 million but generated strong adjusted free cash flow of $126.7 million. Dauch also updated its full-year 2026 sales guidance to a range of $10.8 billion to $10.875 billion.

Term
Q3 2026

“We generated strong cash flow in the quarter while supporting new program launches. At the same time, we are making excellent progress on synergy realization, and we remain focused on delivering long-term value for our stakeholders.”

David C. Dauch, Chairman and Chief Executive Officer
8:01 AM ET 10-Q
Financial Results Next Technology Holding Inc. NXTT

Next Technology Holding Q3 2026 Results: Turns Profitable, Net Income $103M

Next Technology Holding Inc. reported a net loss of $32.2 million for the nine months ended September 30, 2026, compared to a net income of $295.1 million in the prior year period, primarily driven by a $28.1 million loss in other income related to digital asset valuation. The company significantly increased its cash position to $163.9 million following equity issuances and a 100-for-1 reverse stock split effected in August 2026.

Key figure
Net income $103M
8:01 AM ET 8-K
Financial Results Strive, Inc. ASST

Strive Financial Results

Strive, Inc. reported Q3 2026 financial results, highlighted by GAAP net income of $509.0 million and diluted EPS of $5.24. The company significantly expanded its bitcoin holdings, acquiring 8,136 bitcoin during the quarter and an additional 15,124 bitcoin in October 2026. Strive also completed a $609.0 million public offering of its SATS Preferred Stock in October to further its treasury management strategy.

“Strive has continued to successfully execute on its treasury management strategy, delivering a strong bitcoin yield year to date in 2026, which I believe is the primary driver of our common equity's outperformance relative to Bitcoin so far this year. With the recent issuance of SATS, we believe Strive has never been in a better position to generate long-term returns in excess of Bitcoin for our common equity shareholders.”

Matthew Cole, Chairman & Chief Executive Officer
8:01 AM ET 10-Q
Financial Results Cardio Diagnostics Holdings, Inc. CDIO

Cardio Diagnostics Holdings Q3 2026 Results: Net Loss of $1.73M, Loss Widens

Cardio Diagnostics Holdings, Inc. reported a net loss of $5,021,957 for the nine months ended September 30, 2026, compared to $5,032,799 in the prior year period. Revenue remains minimal at $11,630 for the nine-month period, while the company maintains a cash balance of $3,942,882 following a common stock issuance that raised approximately $3.69 million.

Key figure
Net loss $1.73M
8:01 AM ET 8-K
Financial Results Aligos Therapeutics, Inc. ALGS

Aligos Therapeutics Financial Results

Aligos Therapeutics reported third quarter 2026 financial results, including a net loss of $21.9 million and a cash position of $31.1 million. The company highlighted clinical progress in its Phase 2 B-SUPREME study of pevifoscorvir sodium, which remains on track for a topline data readout in late Q3 2027. Current cash reserves are expected to fund operations into the first quarter of 2027.

“This past quarter we continued to advance our Phase 2 B-SUPREME study of pevifoscorvir sodium, which remains on track for the topline data readout in late Q3 2027. With enrollment complete and 70 participants having completed 48 weeks of treatment, the study continues to progress toward the anticipated topline data readout. We remain enthusiastic about pevifoscorvir sodium’s potential, as well as our ASO ALG-170675, which is currently in a Phase 1 study in China with our partner Amoytop. With these recent developments, we believe we are one step closer to our goal of bringing effective therapies to people living with chronic HBV infection.”

Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer
8:01 AM ET 8-K
Investor Presentation US Bancorp \De\ USB

US Bancorp \De\ Investor Presentation

U.S. Bancorp's CFO John Stern and Stephen Philipson, Head of Wealth, Corporate, Commercial and Institutional Banking, are presenting at the BancAnalysts Association of Boston Conference. The company filed the formal presentation slides as an exhibit, covering strategic targets, financial condition, and operational initiatives.

8:00 AM ET 8-K
M&A Deal Acrivon Therapeutics, Inc. ACRV

Acrivon Therapeutics M&A Deal with Aqilion AB

Acrivon Therapeutics has acquired a portfolio of immunology and inflammation (I&I) assets from Swedish biotech Aqilion AB, including the Phase 2-ready oral JAK1 inhibitor ACR-525 and a preclinical PKCθ inhibitor program. The deal establishes I&I as a new strategic pillar for Acrivon, which plans to apply its AP3 precision medicine platform to these assets for indications such as Eosinophilic esophagitis (EoE).

Counterparty
Aqilion AB
7:57 AM ET 8-K
M&A Deal Crown PropTech Acquisitions CPTKW

Crown PropTech Acquisitions M&A Deal with Mkango Rare Earths Limited

Crown PropTech Acquisitions announced that the SEC has declared effective the Form F-4 registration statement for its pending business combination with Mkango Rare Earths Limited. The company has commenced mailing the definitive proxy statement to shareholders for an extraordinary general meeting scheduled for November 25, 2026, to vote on the merger. Upon closing, the combined company is expected to list on Nasdaq under the ticker MKAR.

Counterparty
Mkango Rare Earths Limited
7:51 AM ET 8-K
Financial Results PPL Corp PPL

PPL Financial Results

PPL Corporation reported Q3 2026 GAAP earnings of $0.49 per share and ongoing earnings of $0.54 per share, beating the prior year's results. The company raised its long-term annual EPS growth target to 7% to 9% through 2030 and announced a $25 billion capital plan for 2027-2030. Additionally, PPL's Invitium Energy unit agreed to terms to provide 2 GW of generation capacity for a QTS data center project in Pennsylvania.

Term
Q3 2026

“Our strong third-quarter results reflect continued execution across PPL and keep us on track to meet or exceed the $1.94 per share midpoint of our 2026 ongoing earnings forecast range.”

Vincent Sorgi, PPL President and Chief Executive Officer

“We’re beginning to see those opportunities translate into tangible commercial progress, and today we’re pleased to announce that Invitium Energy has agreed to terms with QTS for approximately 2 GW of generation capacity to serve the QTS data center project in Salem Township, Pennsylvania.”

Vincent Sorgi, PPL President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.